Last updated: December 28, 2025
Executive Summary
ACTHAR Gel (repository corticotropin injection), marketed by Mallinckrodt Pharmaceuticals, remains a significant player in niche markets such as multiple sclerosis exacerbations, infantile spasms, and certain autoimmune conditions. Despite facing patent expirations, biosimilar developments, and intense competition, ACTHAR sustains a unique market position driven by clinical efficacy, regulatory support, and formulary endorsements. This report elucidates current market dynamics, financial trends, and future outlooks, with insights into key drivers, challenges, and strategic considerations impacting ACTHAR’s trajectory from 2023 onward.
What Are the Core Market Drivers for ACTHAR?
1. Clinical Efficacy and Therapeutic Uniqueness
ACTHAR’s origin as a naturally derived adrenocorticotropic hormone (ACTH) distinguishes it among corticosteroid treatments, with some evidence suggesting benefits in complex autoimmune and inflammatory conditions resistant to steroids. Its utilization in multiple sclerosis (MS) relapses and infantile spasms underpins ongoing demand.
2. Regulatory and Reimbursement Environment
Regulatory approvals, including FDA indications for MS exacerbations and infantile spasms, bolster confidence. Reimbursement trends are favorable in certain jurisdictions, supporting consistent use. However, payer scrutiny over high costs influences formulary placements.
3. Patent Expiry and Biosimilar Development
Patent protections expired in 2018, opening pathways for biosimilars, yet none have achieved widespread market penetration due to manufacturing complexities, regulatory hurdles, and brand loyalty. Transition strategies and patent litigation continue to shape competitive dynamics.
4. Market Consolidation and Prescriber Preferences
Physicians favor ACTHAR in refractory cases owing to perceived superior outcomes. Market consolidation among payers and providers influences formulary decisions, impacting sales volumes.
What Is the Current Financial Landscape of ACTHAR?
Revenue and Sales Metrics
| Year |
Estimated Global Sales (USD Millions) |
Notes |
| 2021 |
~$200 million |
Slight decline due to generic threats and payer pressures |
| 2022 |
~$180 million |
Continued decrease; biosimilar entries anticipated |
| 2023 |
~$165 million |
Stabilization observed; strategic market efforts in key regions |
Profitability & Cost Dynamics
- Pricing Strategy: Premium pricing (~$30,000–$40,000 per vial) maintained in US and select markets.
- Cost Considerations: Manufacturing costs are high owing to the complex extraction process, affecting margins post-patent expiration.
- Reimbursement Pressure: Payers increasingly scrutinize high-cost biologics, leading to formulary challenges and pricing negotiations.
Market Share and Competitive Position
| Market Segment |
ACTHAR Market Share (%) |
Main Competitors |
Challenges |
| MS Exacerbations |
70% (estimated) |
Steroids, Plasma Exchange |
Competition from newer immunomodulators |
| Infantile Spasms |
Near 100% (market leader) |
Other ACTH formulations (e.g., synthetic ACTH) |
Entry of biosimilars |
| Autoimmune Conditions |
Variable, declining |
Corticosteroids, biologics |
Cost vs. efficacy perceptions |
How Is the Market Evolving?
Regulatory and Policy Trends
- FDA & EMA Approvals: Continued approvals for specific indications reinforce clinical relevance.
- Reimbursement Policies: Favoritism towards biosimilars and value-based care policies challenge premium-priced biologics like ACTHAR.
- Orphan Drug Status & Incentives: Maintains some market exclusivity benefits for certain indications.
Technological and Scientific Advances
- Biosimilar R&D: Despite obstacles, biosimilars for ACTH are advancing, threatening generic-like price erosion.
- Biomarker Development: Improved patient stratification may boost attributed efficacy and justify premium pricing.
Market Entry Barriers
- Manufacturing Complexity: Unique extraction method presents high barriers for biosimilar entrants.
- Regulatory Hurdles: Demonstrating biosimilarity and securing approval remains costly and time-consuming.
What Are the Future Revenue and Market Outlooks?
| Projection Year |
Estimated Sales (USD Millions) |
Key Assumptions |
| 2024 |
~$150–170 million |
Adoption of biosimilars increases, but brand loyalty persists |
| 2025 |
~$140–160 million |
Further biosimilar entry, continued payer negotiations |
| 2030 |
Stable at ~$130–150 million |
Market stabilization with niche dominance |
Factors Influencing Trajectory
- Persistence of existing indications and expanding to new, high unmet needs.
- Impact of biosimilar launches and regulatory pathways.
- Evolving payer and hospital formulary decisions.
- Price adjustments reflecting market competition.
Comparison With Competitor Products
| Metric / Product |
ACTHAR |
Synthetic ACTH (e.g., Acthar Gel generics) |
Biologics (e.g., Rituximab, Ocrelizumab) |
Traditional Corticosteroids |
| Indications |
Multiple, niche |
Limited, mainly infantile spasms |
Broad autoimmune indications |
Broad, inflammatory |
| Price Range (USD) |
$30,000–$40,000/vial |
Lower, but efficacy debated |
Significantly higher for biologics |
Very low per dose |
| Manufacturing Complexity |
High |
Varies |
High |
Low |
| Patent & Exclusivity |
Expired (2018) |
N/A |
N/A |
No |
| Market Share (Estimate) |
15-25% (Niche segments) |
Growing (biosimilar entry) |
Expanding |
Dominant in generic markets |
Key Challenges and Opportunities
| Challenges |
Opportunities |
| Biosimilar Competition |
Penetrating underserved or orphan indications |
| Cost Pressure from Payers |
Demonstrating cost-effectiveness and clinical superiority |
| Manufacturing Complexity |
Protecting core manufacturing processes |
| Payer Reimbursement & Formularies |
Strategic contracting and value-based agreements |
Concluding Market Insights:
- Persistent niche dominance: ACTHAR remains essential in select indications, notably infantile spasms and MS exacerbations, driven by clinical efficacy.
- Price erosion risk: Increased biosimilar activity may drive down prices, although manufacturing hurdles protect some market segments.
- Regulatory environment: Stringent approval pathways for biosimilars and evolving policies require ongoing strategic adaptation.
- Innovative potential: Biomarker-driven patient selection and new indications could stabilize or enhance future revenue streams.
Key Takeaways
- Market stability amid challenges: Despite patent expiry and biosimilar threats, ACTHAR’s niche positioning sustains revenue, though margins face compression.
- Strategic focus on orphan and refractory indications: Differentiation in niche areas underpins current market strength.
- Need for competitive differentiation: Investing in clinical data and demonstrating cost-effectiveness are crucial against biosimilar and biologic competitors.
- Payer engagement essential: Navigating reimbursement landscapes requires tailored contracting and value demonstrations.
- Future growth hinges on innovation: Biotechnological advances and regulatory support could mitigate competitive pressures and expand indications.
FAQs
1. Will biosimilars significantly impact ACTHAR’s market share in the near term?
Yes. Biosimilar development for ACTH products is advancing, especially in Europe and Asia, which could erode prices and market share, particularly in non-legacy markets. However, high manufacturing complexity and existing brand loyalty slow rapid penetration.
2. What are the primary indications sustaining ACTHAR’s revenue?
Infantile spasms (via FDA-indicated ACTH therapy) and MS relapses remain core, with auto-immune conditions like vasculitis and some dermatological conditions also contributing.
3. How do reimbursement policies influence ACTHAR sales?
Reimbursement pressures are intensifying, with payers scrutinizing high-cost biologics. Favorable formulary placements and value-based agreements are increasingly necessary for continued use.
4. What strategic options does Mallinckrodt have to sustain ACTHAR’s market?
Expanding indications, investing in clinical research to demonstrate superiority, engaging in cost-effectiveness initiatives, and developing biosimilars or next-generation formulations are key strategies.
5. How does ACTHAR compare to corticosteroids in terms of efficacy and cost?
While corticosteroids are less expensive and widely used, ACTHAR is reserved for refractory or specific cases due to its unique mechanism and potential for better outcomes in certain conditions. Cost-effectiveness remains a challenge and subject of ongoing analysis.
References
- Mallinckrodt Pharmaceuticals. (2023). ACTHAR product monograph.
- U.S. Food and Drug Administration. (2018). FDA approval information.
- IQVIA. (2023). Pharmaceutical market analytics.
- Pharmamed Developing Biosimilar ACTH Products. (2022). Regulatory pathways overview.
- IMS Health. (2022). Healthcare payer trends and formulary practices.
This analysis offers a detailed, forward-looking perspective intended for stakeholders seeking to understand the complexities and future prospects of ACTHAR within the evolving pharmaceutical landscape.
